Helix BioPharma Corp. (HBP.TO)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Jacek Antas | Chairman, CEO & Corporate Secretary | 100k | -- | -- |
| Mr. James B. Murphy | Chief Financial Officer | -- | -- | 1957 |
| Ms. Veronika Kandziora | Chief Operating Officer | -- | -- | -- |
| Dr. Davide Guggi Ph.D. | Chief Technology Officer | -- | -- | -- |
| Dr. Jessica Kourniaktis DPHIL | Director of Communications | -- | -- | -- |
| Dr. Thomas Mehrling M.D., Ph.D. | Chief Medical Officer | -- | -- | -- |
Helix BioPharma Corp.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 7
Description
Helix BioPharma Corp. operates as an immune-oncology company in Canada. Its product pipeline comprises L-DOS47, a clinical-stage antibody-enzyme conjugate (AEC) that neutralizes the microenvironment of solid tumors; LDOS001, which is in phase I clinical trial to treat non-small cell lung cancer; LDOS002, which is in phase I/II clinical trial for the treatment of non-small cell lung cancer; LDOS003, which is in phase II clinical trial to treat non-small cell lung cancer; LDOS006, which is in phase Ib/II for the treatment of pancreatic cancer. It develops V-DOS47, an antibody-DOS47 conjugate that targets the vascular endothelial growth factor 2 receptor. It has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with University Hospital Tuebingen to assess the therapeutic response of L-DOS47 in cancer models expressing CEACAM6, with advanced preclinical metabolic imaging. Helix BioPharma Corp. was incorporated in 2008 and is headquartered in Vancouver, Canada.
Corporate Governance
Upcoming Events
June 12, 2025 at 10:59 AM UTC - June 16, 2025 at 12:00 PM UTC
Helix BioPharma Corp. Earnings Date
Recent Events
Recent Events Information Not Available